Abstract
The anti-factor Xa (anti-Xa) assay is a functional assay that facilitates the measurement of antithrombin (AT)-catalyzed inhibition of factor Xa by unfractionated heparin (UFH) and direct inhibition of factor Xa by low-molecular-weight heparin (LMWH) (Kitchen, Br J Haematol 111:397–406, 2000; Walenga et al., Semin Thromb Hemost 11:17–25, 1985; Levine et al., Arch Intern Med 154:49–56, 1994; Barrowcliffe et al., J Pharm Biomed Anal 7:217–226, 1989; Triplett, Ther Drug Monit 1:173–197, 1979; Nelson, Clin Lab Sci 12:359–364, 1999; Laffan and Manning, Dacie and Lewis: practical haematology, Churchill Livingstone, London, pp 465–479, 2001; Olson et al., Arch Pathol Lab Med 122:782–798, 1998). Whilst automated methods for the determination of the abilities of UFH and LMWH to inhibit factor Xa have been available since the 1970s, their cost was viewed to prohibit their broad use in the clinical management of UFH and LMWH until relatively recently. The anti-Xa assay can also be used to guide the determination of therapeutic APTT ranges in the clinical management of UFH (Hirsh and Raschke, Chest 126:188S–203S, 2004). As a result, the anti-Xa assay is commonly viewed as a heparin assay, despite the fact that it actually provides a measure of UFH effect as opposed to a measure of UFH concentration.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Olson J, Arkin C, Brandt J, Cunningham M, Giles A, Koepke J, Witte D (1998) College of American Pathologists conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of unfractionated heparin therapy. Arch Pathol Lab Med 122:782–798
Laffan M, Manning R (2001) Laboratory control of anticoagulant, thrombolytic and anti-platelet therapy (Chapter 18). In: Lewis S, Bain B, Bates I (eds) Dacie and Lewis: practical haematology, 9th edn. Churchill Livingstone, London, pp 465–479
Levine M, Hirsh J, Gent M, Turpie A, Cruisckshank M, Weitz J, Anderson D, Johnson M (1994) A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med 154:49–56
Hirsh J, Raschke R (2004) Heparin and low-molecular-weight heparin. Chest 126: 188S–203S
Monagle P, Barnes C, Ignjatovic V, Furmedge J, Newall F, Chan A, DeRosa L, Hamilton S, Ragg P, Robinson S, Auldist A, Crock C, Rowlands S (2006) Developmental haemostasis: Impact for clinical haemostasis laboratories. Thromb Haemost 95:362–372
Kovacs M, Keeney M, MacKinnon K, Boyle E (1999) Three different chromogenic methods do not give equivalent anti-Xa levels for patients on therapeutic low molecular weight heparin (dalteparin) or unfractionated heparin. Clin Lab Haematol 21:55–60
Kitchen S, Theaker J, Preston F (2000) Monitoring unfractionated heparin therapy: relationship between eight anti-Xa assays and a protamine titration assay. Blood Coagul Fibrinolysis 11:137–144
Ignjatovic V, Summerhayes R, Gan A, Than J, Chan A, Cochrane A, Bennet M, Shann F, Lane G, Ross-Smith M, Monagle P (2007) Monitoring unfractionated heparin (UFH) therapy: which anti factor Xa assay is appropriate? Thromb Res 120:347–351
Ignjatovic V, Summerhayes R, Than J, Gan A, Monagle P (2006) Therapeutic range for unfractionated heparin therapy: age-related differences in response in children. J Thromb Haemost 4:2280–2282
Kitchen S (2000) Problems in laboratory monitoring of heparin dosage. Br J Haematol 111:397–406
Walenga J, Fareed J, Hoppensteadt D (1985) In vitro coagulant and amidolytic methods for evaluating the activity of heparin and a low molecular weight heparin. Semin Thromb Hemost 11:17–25
Barrowcliffe T, Mulloy B, Johnson E, Thomas D (1989) The anticoagulant activity of heparin: measurement and relationship to chemical structure. J Pharm Biomed Anal 7:217–226
Triplett D (1979) Heparin: biochemistry, therapy, and laboratory monitoring. Ther Drug Monit 1:173–197
Nelson D (1999) Current considerations in the use of the APTT in monitoring unfractionated heparin. Clin Lab Sci 12:359–364
Monagle P, Chan A, Massicotte P, Chalmers E, Michelson A (2004) Antithrombotic therapy in children. Chest 126:645S–687S
Ignjatovic V, Furmedge J, Newall F, Chan A, Berry L, Fong C, Cheng K, Monagle P (2006) Age-related differences in heparin response. Thromb Res 118:741–745
Chan A, Black L, Ing C, Brandao L, Williams S (2007) Utility of aPTT in monitoring unfractionated heparin in children. Thromb Res 122:135–136
Kuhle S, Eulmesekian P, Kavanagh B, Massicotte P, Vegh P, Lau A, Mitchell L (2007) Lack of correlation between heparin dose and standard clinical monitoring tests in treatment with unfractionated heparin in critically ill children. Haematologica 92:554–557
Newall F, Ignjatovic V, Johnston L, Summerhayes R, Lane G, Cranswick N, Monagle P (2010) Age is a determinant factor for measures of concentration and effect in children requiring unfractionated heparin. Thromb Haemost 103:1085–1090
Standards N (ed) (1998) Collection, transport and processing of blood specimens for coagulation testing and general performance of coagulation assays. NCCLS, Wayne, PA
Reneke J, Etzell J, Leslie S (1998) Prolonged prothrombin time and activated partial thromboplastin time due to underfilled specimen tubes with 109 mmol/L (3.2 %) citrate anticoagulant. Am J Clin Pathol 109:754–757
Rose VL, Dermott SC, Murray BF, McIver MM, High KA (1993) Decentralized testing for PT and activated PTT using a dry chemistry portable analyzer. Arch Pathol Lab Med 117:611–617
Ignjatovic V, Summerhayes R, Gan A, Than J, Chan A, Cochrane A, Bennet M, Shann F, Lane G, Ross-Smith M, Monagle P (2006) Monitoring unfractionated heparin (UFH) therapy: which anti factor Xa assay is appropriate? J Thromb Haemost 120:347–351
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Humana Press
About this protocol
Cite this protocol
Newall, F. (2013). Anti-factor Xa (Anti-Xa) Assay. In: Monagle, P. (eds) Haemostasis. Methods in Molecular Biology, vol 992. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-339-8_19
Download citation
DOI: https://doi.org/10.1007/978-1-62703-339-8_19
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-62703-338-1
Online ISBN: 978-1-62703-339-8
eBook Packages: Springer Protocols